Here are the names.
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.